ETON peer analysis
Eton Pharmaceuticals (ETON) against its competitors: price, today's move, 1-year return and market value side by side.
ETON and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| DMAC DiaMedica Therapeutics | $9.29 | 0.43% | 31.59% | $498.81M |
| FENC Fennec Pharmaceuticals | $10.54 | 2.93% | 28.54% | $359.09M |
| IONS Ionis Pharmaceuticals | $41.24 | -5.24% | -44.50% | $7.23B |
| LRMR Larimar Therapeutics | $2.37 | -4.05% | -39.07% | $256.59M |
| LXRX Lexicon Pharmaceuticals | $1.44 | 1.41% | 4.35% | $631.84M |
| PHAR Pharming Group | $12.73 | 4.95% | -3.12% | – |
| RARE Ultragenyx | $16.30 | 1.24% | -52.89% | $1.59B |
| TVTX Travere Therapeutics | $49.26 | -2.24% | 40.10% | – |
| ZVRA Zevra Therapeutics | $10.10 | -1.75% | -0.79% | – |
| ETON Eton Pharmaceuticals | $50.81 | -2.63% | 182.12% | $1.49B |
- ETON's peers: DMAC (DiaMedica Therapeutics), FENC (Fennec Pharmaceuticals), IONS (Ionis Pharmaceuticals), LRMR (Larimar Therapeutics), LXRX (Lexicon Pharmaceuticals), PHAR (Pharming Group), RARE (Ultragenyx), TVTX (Travere Therapeutics).
Updated 2026-11-03 11:33 UTC